Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
7.96
-0.35 (-4.21%)
At close: Jul 19, 2024, 4:00 PM
7.99
+0.03 (0.38%)
Pre-market: Jul 22, 2024, 7:28 AM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 557 employees as of December 31, 2023. The number of employees increased by 54 or 10.74% compared to the previous year.
Employees
557
Change (1Y)
54
Growth (1Y)
10.74%
Revenue / Employee
$3,418
Profits / Employee
-$807,259
Market Cap
2.23B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 557 | 54 | 10.74% |
Dec 31, 2022 | 503 | 184 | 57.68% |
Dec 31, 2021 | 319 | 78 | 32.37% |
Dec 31, 2020 | 241 | 93 | 62.84% |
Dec 31, 2019 | 148 | 60 | 68.18% |
Dec 31, 2018 | 88 | 25 | 39.68% |
Dec 31, 2017 | 63 | 12 | 23.53% |
Dec 31, 2016 | 51 | 31 | 155.00% |
Dec 31, 2015 | 20 | 6 | 42.86% |
Dec 31, 2014 | 14 | 9 | 180.00% |
Dec 31, 2013 | 5 | 3 | 150.00% |
Dec 31, 2012 | 2 | 0 | - |
Dec 31, 2011 | 2 | -3 | -60.00% |
Dec 31, 2010 | 5 | 1 | 25.00% |
Dec 31, 2009 | 4 | 2 | 100.00% |
Dec 31, 2008 | 2 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
AMN Healthcare Services | 18,223 |
Amneal Pharmaceuticals | 7,700 |
Patterson Companies | 7,600 |
QuidelOrtho | 7,100 |
Evolent Health | 4,700 |
CONMED | 4,000 |
Privia Health Group | 1,102 |
Beam Therapeutics | 507 |
IOVA News
- 2 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences and Events - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 2 months ago - Iovance (IOVA) stock price could jump by 30% after earnings - Invezz
- 2 months ago - Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire